ArticleScientific reports2025
Neuraminidase-3 activity in toddlers negatively impacts the linear growth status in Bangladeshi children.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Linear growth faltering and stunting in children is associated with inflammation of small gut. Intestinal alkaline phosphatase prevents gut inflammation from subclinical bacterial infection that becomes impaired in the presence of neuraminidase-3 (Neu3) activity. We investigated if total Neu3 in children at 15 months can predict their linear growth at later ages (at 18, 21, and 24 months). We collected data from 189 children enrolled in the Malnutrition and Enteric Disease Study (MAL-ED) birth cohort study in Bangladesh. We determined total Neu3 activity in stool samples at 15 months of age and measured its association with length-for-age z-scores (LAZ) at 18, 21, and 24 months of age, in addition to their socio-demographic conditions using bi-variate and multivariable linear regression analyses. We found that total Neu3 at 15 months was negatively associated with the LAZ-score at 18 (regression coefficient -0.004, 95% CI -0.006 to -0.001, p < 0.01), 21 (-0.003, 95% CI -0.006, -0.001, p < 0.01), and 24 (-0.004, 95% CI -0.006, -0.001, p < 0.01) months of age after adjusting the covariates. In conclusion, total neuraminidase-3 in stool is a significant predictor of linear growth in young children and would be key in early detection of linear growth faltering and stunting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.